Literature DB >> 12095824

Autoantibodies to transducin in a patient with melanoma-associated retinopathy.

Michael J Potter1, Grazyna Adamus, Shelagh M Szabo, Rehwa Lee, Kam Mohaseb, Darren Behn.   

Abstract

PURPOSE: To report novel immunoreactivity in a patient with melanoma-associated retinopathy.
DESIGN: Retrospective case report and experimental study.
METHODS: A 32-year-old woman with a history of metastatic melanoma presented with bilateral decreased visual acuity. Electroretinography, Goldmann perimetry, immunohistochemistry, and Western blotting of her serum were performed.
RESULTS: Electroretinography showed a "negative" B-wave. Paracentral and central scotomas were observed on Goldmann perimetry. Antibodies to a retinal transducin were demonstrated by Western blotting. No immunoreactivity to retinal bipolar cells was detected by immunohistochemistry.
CONCLUSION: Melanoma-associated retinopathy can be related to a variety of antiretinal antibodies. Recognition of transducin, a novel melanoma-associated retinopathy antigen, may be important for identifying and treating patients with night blindness and melanoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095824     DOI: 10.1016/s0002-9394(02)01431-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

Review 1.  The need for standardization of antiretinal antibody detection and measurement.

Authors:  Farzin Forooghian; Ian M Macdonald; John R Heckenlively; Elise Héon; Lynn K Gordon; John J Hooks; Barbara Detrick; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2008-07-30       Impact factor: 5.258

2.  Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells.

Authors:  Anuradha Dhingra; Marie E Fina; Adam Neinstein; David J Ramsey; Ying Xu; Gerald A Fishman; Kenneth R Alexander; Haohua Qian; Neal S Peachey; Ronald G Gregg; Noga Vardi
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

3.  Treatment of melanoma-associated retinopathy.

Authors:  Steven F Powell; Arkadiusz Z Dudek
Journal:  Curr Treat Options Neurol       Date:  2010-01       Impact factor: 3.598

4.  Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.

Authors:  Yukiko Morita; Kazuhiro Kimura; Youichiro Fujitsu; Atsushi Enomoto; Shinji Ueno; Mineo Kondo; Koh-Hei Sonoda
Journal:  Jpn J Ophthalmol       Date:  2014-01-29       Impact factor: 2.447

5.  Cancer-associated retinopathy (CAR) with electronegative ERG: a case report.

Authors:  Griet Goetgebuer; Anna-Maria Kestelyn-Stevens; Jean-Jacques De Laey; Philippe Kestelyn; Bart P Leroy
Journal:  Doc Ophthalmol       Date:  2007-08-25       Impact factor: 2.379

Review 6.  Autoimmune retinopathy: a review and summary.

Authors:  John R Heckenlively; Henry A Ferreyra
Journal:  Semin Immunopathol       Date:  2008-04-12       Impact factor: 9.623

7.  Molecular biomarkers for autoimmune retinopathies: significance of anti-transducin-alpha autoantibodies.

Authors:  Grazyna Adamus; Lori Brown; Richard G Weleber
Journal:  Exp Mol Pathol       Date:  2009-09-08       Impact factor: 3.362

Review 8.  Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy.

Authors:  Grazyna Adamus
Journal:  Autoimmun Rev       Date:  2009-01-23       Impact factor: 9.754

9.  Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction.

Authors:  Mineo Kondo; Rikako Sanuki; Shinji Ueno; Yuji Nishizawa; Naozumi Hashimoto; Hiroshi Ohguro; Shuichi Yamamoto; Shigeki Machida; Hiroko Terasaki; Grazyna Adamus; Takahisa Furukawa
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

10.  Autoimmune retinopathy in systemic lupus erythematosus: histopathologic features.

Authors:  Xiaoguang Cao; Rachel J Bishop; Farzin Forooghian; Youngeun Cho; Robert N Fariss; Chi-Chao Chan
Journal:  Open Ophthalmol J       Date:  2009-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.